Journal of Infection最新文献

{"title":"Alternating magnetic fields (AMF) and linezolid reduce Staphylococcus aureus biofilm in a large animal implant model","authors":"Isuru A. Somawardana ,&nbsp;Bibin Prasad ,&nbsp;Walker Kay ,&nbsp;Connor Hunt ,&nbsp;Jacob Adams ,&nbsp;Brooke Kawaguchi ,&nbsp;Tyler B. Smith ,&nbsp;Nicholas Ashton ,&nbsp;Varun Sadaphal ,&nbsp;John Tepper ,&nbsp;Marguerite Monogue ,&nbsp;Josue I. Ramirez ,&nbsp;Olivia D. Jones ,&nbsp;John M. Shelton ,&nbsp;Bret M. Evers ,&nbsp;Rousselle Serge ,&nbsp;Christine Pybus ,&nbsp;Dustin Williams ,&nbsp;Rajiv Chopra ,&nbsp;David E. Greenberg","doi":"10.1016/j.jinf.2024.106271","DOIUrl":"10.1016/j.jinf.2024.106271","url":null,"abstract":"<div><h3>Objectives</h3><p>We aimed to evaluate the effectiveness of alternating magnetic fields (AMF) combined with antibiotics in reducing <em>Staphylococcus aureus</em> biofilm on metal implants in a large animal model, compared to antibiotics alone.</p></div><div><h3>Methods</h3><p>Metal plates were inoculated with a clinical MRSA strain and then implanted into thirty-three ewes divided into three groups: positive control, linezolid only, and a combination of linezolid and AMF. Animals had either titanium or cobalt-chrome plates and were sacrificed at 5 or 21 days post-implantation. Blood and tissue samples were collected at various time points post-AMF treatment.</p></div><div><h3>Results</h3><p><em>In vivo</em> efficacy studies demonstrated significant biofilm reduction on titanium and cobalt-chrome implants with AMF-linezolid combination treatment compared to controls. Significant bacterial reductions were also observed in surrounding tissues and bones. Cytokine analysis showed improved inflammatory responses with combination therapy, and histopathology confirmed reduced inflammation, necrosis, and bacterial presence, especially at 5 days post-implantation.</p></div><div><h3>Conclusions</h3><p>This study demonstrates that combining AMF with antibiotics significantly reduces biofilm-associated infections on metal implants in a large animal model. Numerical simulations confirmed targeted heating, and <em>in vivo</em> results showed substantial bacterial load reduction and reduced inflammatory response. These findings support the potential of AMF as a non-invasive treatment for prosthetic joint infections.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106271"},"PeriodicalIF":14.3,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002056/pdfft?md5=7b1b73004289824ab254d6287709619c&pid=1-s2.0-S0163445324002056-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary bacterial infection after lung transplantation: risk factors and impact on short-term mortality","authors":"Rong Gao ,&nbsp;Wenjing Wang ,&nbsp;Ting Qian ,&nbsp;Xiaoshan Li ,&nbsp;Hang Yang ,&nbsp;Tianyang Liu ,&nbsp;Huaqing Yu ,&nbsp;Lin Man ,&nbsp;Min Xiong ,&nbsp;Jingyu Chen ,&nbsp;Bo Wu","doi":"10.1016/j.jinf.2024.106273","DOIUrl":"10.1016/j.jinf.2024.106273","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the risk factors for pulmonary bacterial infection (PBI) after lung transplantation (LTX) and to evaluate the impact of PBI on short-term postoperative mortality.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data on 549 recipients who underwent LTX at the Affiliated Wuxi People's Hospital of Nanjing Medical University, China, between January 2018 and December 2021. The risk factors for PBI after LTX were explored by univariate analysis and multivariate logistic regression. Cox proportional hazards regression models were used to estimate the hazard ratios (<em>HR</em>) and 95% confidence intervals (<em>CI</em>) of one-, two-, and three-year mortality. Subgroup analysis was performed by the time of postoperative PBI (≤7 days or 8–30 day after surgery).</div></div><div><h3>Results</h3><div>The incidence of postoperative PBI in 549 recipients was 82.70% (454/549). Preoperative history of infections with multidrug-resistant bacteria (<em>OR</em> 12.34, 95% <em>CI</em> 1.69–1572.39), <em>Acinetobacter baumannii</em> infection in donor (<em>OR</em> 3.08, 95% <em>CI</em> 1.26–9.66), and longer cold ischemia time (<em>OR</em> 1.16, 95% <em>CI</em> 1.03–1.32) were risk factors for postoperative PBI. Postoperative PBI was associated with one-year (<em>HR</em> 1.80, 95% <em>CI</em> 1.09–2.96), two-year (<em>HR</em> 1.91, 95% <em>CI</em> 1.20–3.04), and three-year mortality (<em>HR</em> 2.03, 95% <em>CI</em> 1.29–3.19). Subgroup analysis showed that PBI within 7 days after surgery was associated with one-year (<em>HR</em> 1.86, 95% <em>CI</em> 1.12–3.08), two-year (<em>HR</em> 1.99, 95% <em>CI</em> 1.25–3.17), and three-year mortality (<em>HR</em> 2.13, 95% <em>CI</em> 1.35–3.36), while PBI at 8–30 days after surgery was not associated with short-term mortality (one-year: <em>HR</em> 1.36, 95% <em>CI</em> 0.69–2.69; two-year: <em>HR</em> 1.48, 95% <em>CI</em> 0.80–2.76; three-year: <em>HR</em> 1.51, 95% <em>CI</em> 0.82–2.77).</div></div><div><h3>Conclusions</h3><div>Donor-recipient and surgical factors are risk factors for PBI after LTX. Active prevention and treatment of PBI within the first 7 days after surgery may improve short-term survival.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106273"},"PeriodicalIF":14.3,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S016344532400207X/pdfft?md5=27212e3164b3c5af6756fba7c46348cb&pid=1-s2.0-S016344532400207X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of infection with TEM β-lactamase-producing Escherichia coli with Pan-β-lactam resistance","authors":"Ángel Rodríguez-Villodres ,&nbsp;José Manuel Ortiz de la Rosa ,&nbsp;Lydia Gálvez-Benítez ,&nbsp;María Luisa Gascón ,&nbsp;Germán Peñalva ,&nbsp;Francisco J. Dorado Pardo ,&nbsp;Carlos S. Casimiro-Soriguer ,&nbsp;Marta Rodríguez Rodríguez ,&nbsp;Rosario Amaya Villar ,&nbsp;José Miguel Cisneros ,&nbsp;José Antonio Lepe","doi":"10.1016/j.jinf.2024.106268","DOIUrl":"10.1016/j.jinf.2024.106268","url":null,"abstract":"<div><h3>Background</h3><p>Antimicrobial resistance is a critical global health issue, significantly contributing to patient mortality. Recent antibiotic developments have aimed to counteract carbapenemase-producing Enterobacterales; however, the impact of their use on the emergence of antibiotic resistance is unknown. This study investigates the first case of a non-carbapenemase-producing, pan-β-lactam-resistant <em>Escherichia coli</em> strain from a patient previously treated with ceftolozane–tazobactam and cefiderocol.</p></div><div><h3>Methods</h3><p>This study describes the clinical progression of a 39-year-old ICU patient who developed multiple infections, culminating in the isolation of a pan-β-lactam-resistant <em>E. coli</em> strain (EC554). The resistance profile was characterised through MIC determination, whole-genome sequencing, the use of the β-lactam inactivation method<em>,</em> RT-qPCR, efflux pump inhibition assays, outer membrane protein analysis, and <em>bla</em>_<em>TEM</em> transformation.</p></div><div><h3>Findings</h3><p>The EC554 isolate displayed resistance to all tested β-lactams and β-lactam–β-lactamase inhibitor combinations. Whole-genome sequencing revealed four plasmids in EC554, with the only β-lactamase gene being blaTEM-252 on the pEC554-PBR-X1-X1 plasmid. We found that the extremely resistant phenotype was attributable to a combination of different mechanisms: a high expression of TEM-252, efflux pump activity, porin loss, and PBP3 mutations.</p></div><div><h3>Interpretation</h3><p>The findings illustrate the complex interplay of multiple resistance mechanisms in <em>E. coli</em>, highlighting the potential for high-level resistance even without carbapenemase production. This study underscores the importance of comprehensively characterising resistance mechanisms in order to inform effective treatment strategies and mitigate the spread of resistant strains.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106268"},"PeriodicalIF":14.3,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002020/pdfft?md5=816384286b4ff4287703330c29aaf27d&pid=1-s2.0-S0163445324002020-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The recent rapid rise in pertussis in Chaoyang District, Beijing: Improved recognition and diagnostic capabilities","authors":"Fang Liu,&nbsp;Zhen Li,&nbsp;Yingxue Hu,&nbsp;Bin Jia,&nbsp;Jianxin Ma","doi":"10.1016/j.jinf.2024.106272","DOIUrl":"10.1016/j.jinf.2024.106272","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106272"},"PeriodicalIF":14.3,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002068/pdfft?md5=85df86c47853d188a048add09e8fd8c4&pid=1-s2.0-S0163445324002068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials” [J Infect 89 (2024) 106187]","authors":"Kristoffer Grundtvig Skaarup ,&nbsp;Mats Christian Højbjerg Lassen ,&nbsp;Daniel Modin ,&nbsp;Niklas Dyrby Johansen ,&nbsp;Matthew M. Loiacono ,&nbsp;Rebecca C. Harris ,&nbsp;Jason K.H. Lee ,&nbsp;Marine Dufournet ,&nbsp;Orly Vardeny ,&nbsp;Alexander Peikert ,&nbsp;Brian Claggett ,&nbsp;Scott D. Solomon ,&nbsp;Jens Ulrik Stæhr Jensen ,&nbsp;Tor Biering-Sørensen","doi":"10.1016/j.jinf.2024.106270","DOIUrl":"10.1016/j.jinf.2024.106270","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106270"},"PeriodicalIF":14.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002044/pdfft?md5=f7a4d0e96f39a38b4bf56b58adc5cb94&pid=1-s2.0-S0163445324002044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chatbots are just as good as professors in both factual recall and clinical scenario analysis: Emergence of a new tool in clinical microbiology and infectious disease","authors":"Chun-Sheng Wang,&nbsp;Yu Hsiao,&nbsp;Cheng-Han Tsou,&nbsp;Chi-Ching Tsang,&nbsp;Susanna K.P. Lau,&nbsp;Patrick C.Y. Woo","doi":"10.1016/j.jinf.2024.106274","DOIUrl":"10.1016/j.jinf.2024.106274","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106274"},"PeriodicalIF":14.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002081/pdfft?md5=430b0effa6cc1c4aec0b734f856a3322&pid=1-s2.0-S0163445324002081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiology and outcomes of tubo-ovarian abscesses: A 5-year cohort of 105 cases","authors":"Giulia Micheli,&nbsp;Guillaume Parpex,&nbsp;Asmaa Tazi,&nbsp;Elena Holeindre,&nbsp;Julien Loubinoux,&nbsp;Cécile Guyonnet,&nbsp;Jeanne Reboul-Marty,&nbsp;Claire Poyart,&nbsp;Charles Chapron,&nbsp;Pauline Richebé,&nbsp;Etienne Canouï,&nbsp;Roberto Cauda,&nbsp;Martin Belan,&nbsp;Camille Rasmussen,&nbsp;Louis Marcellin,&nbsp;Laetitia Campin,&nbsp;Caroline Charlier","doi":"10.1016/j.jinf.2024.106253","DOIUrl":"10.1016/j.jinf.2024.106253","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106253"},"PeriodicalIF":14.3,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001877/pdfft?md5=a0ffaa763ae627cf15ab91d603d3c903&pid=1-s2.0-S0163445324001877-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning to attribute the source of Campylobacter infections in the United States: A retrospective analysis of national surveillance data","authors":"Ben Pascoe ,&nbsp;Georgina Futcher ,&nbsp;Johan Pensar ,&nbsp;Sion C. Bayliss ,&nbsp;Evangelos Mourkas ,&nbsp;Jessica K. Calland ,&nbsp;Matthew D. Hitchings ,&nbsp;Lavin A. Joseph ,&nbsp;Charlotte G. Lane ,&nbsp;Tiffany Greenlee ,&nbsp;Nicolas Arning ,&nbsp;Daniel J. Wilson ,&nbsp;Keith A. Jolley ,&nbsp;Jukka Corander ,&nbsp;Martin C.J. Maiden ,&nbsp;Craig T. Parker ,&nbsp;Kerry K. Cooper ,&nbsp;Erica B. Rose ,&nbsp;Kelli Hiett ,&nbsp;Beau B. Bruce ,&nbsp;Samuel K. Sheppard","doi":"10.1016/j.jinf.2024.106265","DOIUrl":"10.1016/j.jinf.2024.106265","url":null,"abstract":"<div><h3>Objectives</h3><p>Integrating pathogen genomic surveillance with bioinformatics can enhance public health responses by identifying risk and guiding interventions. This study focusses on the two predominant <em>Campylobacter</em> species, which are commonly found in the gut of birds and mammals and often infect humans via contaminated food. Rising incidence and antimicrobial resistance (AMR) are a global concern, and there is an urgent need to quantify the main routes to human infection.</p></div><div><h3>Methods</h3><p>During routine US national surveillance (2009–2019), 8856 <em>Campylobacter</em> genomes from human infections and 16,703 from possible sources were sequenced. Using machine learning and probabilistic models, we target genetic variation associated with host adaptation to attribute the source of human infections and estimate the importance of different disease reservoirs.</p></div><div><h3>Results</h3><p>Poultry was identified as the primary source of human infections, responsible for an estimated 68% of cases, followed by cattle (28%), and only a small contribution from wild birds (3%) and pork sources (1%). There was also evidence of an increase in multidrug resistance, particularly among isolates attributed to chickens.</p></div><div><h3>Conclusions</h3><p>National surveillance and source attribution can guide policy, and our study suggests that interventions targeting poultry will yield the greatest reductions in campylobacteriosis and spread of AMR in the US.</p></div><div><h3>Data availability</h3><p>All sequence reads were uploaded and shared on NCBI’s Sequence Read Archive (SRA) associated with BioProjects; PRJNA239251 (CDC / PulseNet surveillance), PRJNA287430 (FSIS surveillance), PRJNA292668 &amp; PRJNA292664 (NARMS) and PRJNA258022 (FDA surveillance). Publicly available genomes, including reference genomes and isolates sampled worldwide from wild birds are associated with BioProject accessions: PRJNA176480, PRJNA177352, PRJNA342755, PRJNA345429, PRJNA312235, PRJNA415188, PRJNA524300, PRJNA528879, PRJNA529798, PRJNA575343, PRJNA524315 and PRJNA689604. Contiguous assemblies of all genome sequences compared are available at Mendeley data (assembled <em>C. coli</em> genomes doi: 10.17632/gxswjvxyh3.1; assembled <em>C. jejuni</em> genomes doi: 10.17632/6ngsz3dtbd.1) and individual project and accession numbers can be found in <span><span>Supplementary tables S1 and S2</span></span>, which also includes pubMLST identifiers for assembled genomes. Figshare (10.6084/m9.figshare.20279928). Interactive phylogenies are hosted on microreact separately for <em>C. jejuni</em> (<span><span>https://microreact.org/project/pascoe-us-cjejuni</span><svg><path></path></svg></span>) and <em>C. coli</em> (<span><span>https://microreact.org/project/pascoe-us-ccoli</span><svg><path></path></svg></span>).</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106265"},"PeriodicalIF":14.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001993/pdfft?md5=c0b37a24b73f499375e261dec42d2063&pid=1-s2.0-S0163445324001993-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial","authors":"Ellie McDonald ,&nbsp;Laure F. Pittet ,&nbsp;Simone E. Barry ,&nbsp;Marc Bonten ,&nbsp;John Campbell ,&nbsp;Julio Croda ,&nbsp;Mariana G. Croda ,&nbsp;Margareth Pretti Dalcolmo ,&nbsp;Andrew Davidson ,&nbsp;Fernando F. de Almeida e Val ,&nbsp;Glauce dos Santos ,&nbsp;Kaya Gardiner ,&nbsp;Grace Gell ,&nbsp;Amanda Gwee ,&nbsp;Ann Krastev ,&nbsp;Marcus Vinícius Guimaraes Lacerda ,&nbsp;Michaela Lucas ,&nbsp;David J. Lynn ,&nbsp;Laurens Manning ,&nbsp;Nick McPhate ,&nbsp;Nigel Curtis","doi":"10.1016/j.jinf.2024.106267","DOIUrl":"10.1016/j.jinf.2024.106267","url":null,"abstract":"<div><h3>Background</h3><div>Some individuals have a persistence of symptoms following both COVID-19 (post-acute COVID-19 syndrome; PACS) and other viral infections. This study used prospectively collected data from an international trial to compare symptoms following COVID-19 and non-COVID-19 respiratory illness, to identify factors associated with the risk of PACS, and to explore symptom patterns before and after COVID-19 and non-COVID-19 respiratory illnesses.</div></div><div><h3>Methods</h3><div>Data from a multicentre randomised controlled trial (BRACE trial) involving healthcare workers across four countries were analysed. Symptom data were prospectively collected over 12 months, allowing detailed characterisation of symptom patterns. Participants with COVID-19 and non-COVID-19 respiratory illness episodes were compared, focussing on symptom severity, duration (including PACS using NICE and WHO definitions), and pre-existing symptoms.</div></div><div><h3>Findings</h3><div>Compared to those with a non-COVID-19 illness, participants with COVID-19 had significantly more severe illness (OR 7·4, 95%CI 5·6–9·7). Symptom duration meeting PACS definitions occurred in a higher proportion of COVID-19 cases than non-COVID-19 respiratory controls using both the NICE definition (2·5% vs 0·5%, OR 6·6, 95%CI 2·4–18·3) and the WHO definition (8·8% vs 3·7%, OR 2·5, 95%CI 1·4–4·3). When considering only participants with COVID-19, age 40-59 years (aOR 2·8, 95%CI 1·3–6·2), chronic respiratory disease (aOR 5·5, 95%CI 1·3–23·1), and pre-existing symptoms (aOR 3·0, 95%CI 1·4–6·3) were associated with an increased risk of developing PACS. Symptoms associated with PACS were also reported by participants in the months preceding their COVID-19 or non-COVID-19 respiratory illnesses (32% fatigue and muscle ache, 11% intermittent cough and shortness of breath).</div></div><div><h3>Interpretation</h3><div>Healthcare workers with COVID-19 were more likely to have severe and longer-lasting symptoms than those with a non-COVID-19 respiratory illness, with a higher proportion meeting the WHO or NICE definitions of PACS. Age, chronic respiratory disease, and pre-existing symptoms increased the risk of developing PACS following COVID-19.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106267"},"PeriodicalIF":14.3,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: Results of a prospective trial (ED-POC)","authors":"Mary E. Chapman ,&nbsp;Nathan J. Brendish ,&nbsp;Matthew Morris ,&nbsp;C. Mirella Spalluto ,&nbsp;Christopher J. McCormick ,&nbsp;Helen E. Moyses ,&nbsp;Tristan W. Clark","doi":"10.1016/j.jinf.2024.106264","DOIUrl":"10.1016/j.jinf.2024.106264","url":null,"abstract":"<div><h3>Background</h3><p>A novel single-use, analyser-free, molecular point-of-care test for SARS-CoV-2 (Veros COVID-19 test, Sherlock Biosciences) could reduce time to results and improve patient care and flow in the emergency department (ED), but its performance in this setting is unknown.</p></div><div><h3>Methods</h3><p>Adults aged ≥18 years presenting to Southampton General Hospital (UK) with suspected COVID-19 were tested with the Veros COVID-19 test in addition to standard of care near-patient PCR. Measures of diagnostic accuracy were calculated for the Veros COVID-19 test stratified by Ct value. Discrepant results underwent viral culture.</p></div><div><h3>Findings</h3><p>Between Jan 16 and May 2, 2023, 400 patients were enrolled with a median (IQR) age of 60 (34−77) and 141 (35·3%) were SARS-CoV-2 positive by PCR. The Veros test gave valid results on the first test in 384 (96·0%), and sensitivity and specificity were 127/141 (90·1%, 95%CI 83·9–94·5) and 258/259 (99·6%, 95%CI 97·9–100) overall. For those with high or moderate viral load (Ct ≤30), sensitivity was 125/129 (96·9%, 95%CI 92·3–99·2). One (7·1%) of 14 PCR positive/Veros test negative samples was culture positive. Median (IQR) time from sample collection to result was 19 (18−20) mins with the Veros test versus 73 (59−92) mins with PCR (p &lt; 0·0001).</p></div><div><h3>Interpretation</h3><p>The Veros COVID-19 test generated results in near real-time, around 1 h sooner than rapid, near-patient, analyser-based PCR, and accuracy was excellent for samples with moderate and high viral loads. The Veros test represents a step-change in molecular diagnostics for infection and could significantly reduce time to results and improve patient management in EDs and other settings.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106264"},"PeriodicalIF":14.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001981/pdfft?md5=0fade4443d05eaeb8067a4edf39e5a40&pid=1-s2.0-S0163445324001981-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}